Bevacizumab in Combination with Interferon Alpha in Metastatic Renal Cell Carcinoma: The Emerging Evidence of Its Therapeutic Value

2011 ◽  
Vol 3 ◽  
pp. 59-69
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Value

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.

1985 ◽  
Vol 3 (11) ◽  
pp. 1522-1528 ◽  
Author(s):  
J R Quesada ◽  
A Rios ◽  
D Swanson ◽  
P Trown ◽  
J U Gutterman
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Neutralizing Antibodies ◽  
Recombinant Dna ◽  
Lung Parenchyma ◽  
High Dose ◽  
Node Metastases

Fifty-six patients with metastatic renal cell carcinoma (RCC) were treated with recombinant DNA-derived interferon alpha (rIFN alpha A). The first 30 patients were randomized between doses of 2 X 10(6) U/m2 and 20 X 10(6) U/m2 intramuscularly daily. No complete (CR) or partial (PR) remissions were achieved in 15 patients receiving the low dose. In contrast, 27% of those receiving the high dose achieved CR or PR. Subsequently, 26 additional patients were given the high dose and achieved a 31% response rate. Remissions lasted from 1 to more than 12 months (median, 3 months). Responses occurred predominantly in lung parenchyma or mediastinal node metastases. Toxicity of the high dose required dose reduction in 50% of the patients. Neutralizing antibodies to rIFN alpha A developed in seven of 12 responsive (58%) and nine of 29 (31%) nonresponsive patients (P = greater than .5). The median duration of remission among the antibody-positive and antibody-negative patients were 2 and 10 months, respectively (P = .009). The clinical significance of the antibodies to rIFN alpha A remains unclear, but the coincidence between the detection of antibodies and the early relapse of the disease in some responsive patients suggests that these antibodies may abrogate the biologic activity of rIFN alpha A. This effect, however, was not associated with adverse clinical sequelae.

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5019-LBA5019 ◽  
Author(s):  
B. I. Rini ◽  
S. Halabi ◽  
J. Rosenberg ◽  
W. M. Stadler ◽  
D. A. Vaena ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Interferon Alpha ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Final Text

LBA5019 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document